Previous 10 | Next 10 |
Vascular Biogenics Ltd. (VBLT) Q4 2021 Earnings Conference Call March 22, 2022 8:30 a.m. ET Company Participants Dror Harats - CEO Sam Backenroth - CFO Dan Ferry - LifeSci Advisors, IR Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Susan Chor - Oppenheimer & Co. Swa...
The following slide deck was published by Vascular Biogenics Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Vascular Biogenics Ltd. 2021 Q4 - Results - Earnings Call Presentation
VBL Therapeutics press release (NASDAQ:VBLT): FY GAAP EPS of -$0.45 misses by $0.03. Revenue of $0.77M (-16.3% Y/Y) beats by $0.02M. At December 31, 2021, cash, cash equivalents, short-term bank deposits and restricted bank deposits of $53.5 million. For further details see: VBL T...
OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023 Completed patient enrollment in the 409 patient OVAL Phase 3 registration ...
VBL Therapeutics (NASDAQ:VBLT) is scheduled to announce FY earnings results on Wednesday, March 23rd, before market open. The consensus EPS Estimate is -$0.42 (+23.6% Y/Y) and the consensus Revenue Estimate is $0.75M (-18.5% Y/Y). For further details see: VBL Therapeutics FY 2021 Earnin...
AGFY, AYRO, CL, OTCQX:CRLBF, CTAS, EVGO, GIS, OTCPK:HNHAF, HTHT, HYZN, JKS, MOGO, PDSB, OTCPK:TCEHY, VBLT, WGO, YOU For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today a...
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today a...
VBL Therapeutics (NASDAQ:VBLT) said an independent data safety monitoring committee recommended to continue a phase 3 trial of its drug Ofra-vec to treat platinum-resistant ovarian cancer, following a review of data from 370 patients. The company noted that enrollment in the ph...
Phase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe, Israel, and Japan Top-line data from progression free survival (PFS) primary endpoint expected in 2H 2022 expected to have the potential to support a Biologics License Application (BLA) subm...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...